Industry Reports

Liver Cancer - Pipeline Review, H2 2016

Friday, Dec 30, 2016

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cancer – Pipeline Review, H2 2016, provides an overview of the Liver Cancer (Oncology) pipeline landscape.


Liver cancer starts in the liver. The risk factors for liver cancer include hepatitis, cirrhosis, or scarring of liver, being male and having low weight at birth. Symptoms include a lump or pain on the right side of the abdomen and yellowing of the skin. Treatment of liver cancer may include chemotherapy, radiation and surgery.


Report Highlights


Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Liver Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.


The Liver Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Liver Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 17, 76, 52, 8, 121 and 19 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 15, 8, 1, 30 and 3 molecules, respectively.


Liver Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.